These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 27956380)

  • 1. Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade.
    Nathanson T; Ahuja A; Rubinsteyn A; Aksoy BA; Hellmann MD; Miao D; Van Allen E; Merghoub T; Wolchok JD; Snyder A; Hammerbacher J
    Cancer Immunol Res; 2017 Jan; 5(1):84-91. PubMed ID: 27956380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic basis for clinical response to CTLA-4 blockade in melanoma.
    Snyder A; Makarov V; Merghoub T; Yuan J; Zaretsky JM; Desrichard A; Walsh LA; Postow MA; Wong P; Ho TS; Hollmann TJ; Bruggeman C; Kannan K; Li Y; Elipenahli C; Liu C; Harbison CT; Wang L; Ribas A; Wolchok JD; Chan TA
    N Engl J Med; 2014 Dec; 371(23):2189-2199. PubMed ID: 25409260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a neoantigen epitope in a melanoma patient with good response to anti-PD-1 antibody therapy.
    Nonomura C; Otsuka M; Kondou R; Iizuka A; Miyata H; Ashizawa T; Sakura N; Yoshikawa S; Kiyohara Y; Ohshima K; Urakami K; Nagashima T; Ohnami S; Kusuhara M; Mitsuya K; Hayashi N; Nakasu Y; Mochizuki T; Yamaguchi K; Akiyama Y
    Immunol Lett; 2019 Apr; 208():52-59. PubMed ID: 30880120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population-level distribution and putative immunogenicity of cancer neoepitopes.
    Wood MA; Paralkar M; Paralkar MP; Nguyen A; Struck AJ; Ellrott K; Margolin A; Nellore A; Thompson RF
    BMC Cancer; 2018 Apr; 18(1):414. PubMed ID: 29653567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.
    Łuksza M; Riaz N; Makarov V; Balachandran VP; Hellmann MD; Solovyov A; Rizvi NA; Merghoub T; Levine AJ; Chan TA; Wolchok JD; Greenbaum BD
    Nature; 2017 Nov; 551(7681):517-520. PubMed ID: 29132144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
    Van Allen EM; Miao D; Schilling B; Shukla SA; Blank C; Zimmer L; Sucker A; Hillen U; Foppen MHG; Goldinger SM; Utikal J; Hassel JC; Weide B; Kaehler KC; Loquai C; Mohr P; Gutzmer R; Dummer R; Gabriel S; Wu CJ; Schadendorf D; Garraway LA
    Science; 2015 Oct; 350(6257):207-211. PubMed ID: 26359337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.
    Cohen CJ; Gartner JJ; Horovitz-Fried M; Shamalov K; Trebska-McGowan K; Bliskovsky VV; Parkhurst MR; Ankri C; Prickett TD; Crystal JS; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
    J Clin Invest; 2015 Oct; 125(10):3981-91. PubMed ID: 26389673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The neoepitope landscape of breast cancer: implications for immunotherapy.
    Narang P; Chen M; Sharma AA; Anderson KS; Wilson MA
    BMC Cancer; 2019 Mar; 19(1):200. PubMed ID: 30832597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes.
    Lu T; Wang S; Xu L; Zhou Q; Singla N; Gao J; Manna S; Pop L; Xie Z; Chen M; Luke JJ; Brugarolas J; Hannan R; Wang T
    Sci Immunol; 2020 Feb; 5(44):. PubMed ID: 32086382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer.
    Zou XL; Li XB; Ke H; Zhang GY; Tang Q; Yuan J; Zhou CJ; Zhang JL; Zhang R; Chen WY
    Front Immunol; 2021; 12():689076. PubMed ID: 34992591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma.
    Miller A; Asmann Y; Cattaneo L; Braggio E; Keats J; Auclair D; Lonial S; ; Russell SJ; Stewart AK
    Blood Cancer J; 2017 Sep; 7(9):e612. PubMed ID: 28937974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Microenvironment and Immunotherapy: The Whole Picture Is Better Than a Glimpse.
    Church SE; Galon J
    Immunity; 2015 Oct; 43(4):631-3. PubMed ID: 26488814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoantigen landscape dynamics during human melanoma-T cell interactions.
    Verdegaal EM; de Miranda NF; Visser M; Harryvan T; van Buuren MM; Andersen RS; Hadrup SR; van der Minne CE; Schotte R; Spits H; Haanen JB; Kapiteijn EH; Schumacher TN; van der Burg SH
    Nature; 2016 Aug; 536(7614):91-5. PubMed ID: 27350335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
    Wu X; Giobbie-Hurder A; Liao X; Connelly C; Connolly EM; Li J; Manos MP; Lawrence D; McDermott D; Severgnini M; Zhou J; Gjini E; Lako A; Lipschitz M; Pak CJ; Abdelrahman S; Rodig S; Hodi FS
    Cancer Immunol Res; 2017 Jan; 5(1):17-28. PubMed ID: 28003187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy.
    Bronstein Y; Ng CS; Hwu P; Hwu WJ
    AJR Am J Roentgenol; 2011 Dec; 197(6):W992-W1000. PubMed ID: 22109345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exome Sequencing to Predict Neoantigens in Melanoma.
    Pritchard AL; Burel JG; Neller MA; Hayward NK; Lopez JA; Fatho M; Lennerz V; Wölfel T; Schmidt CW
    Cancer Immunol Res; 2015 Sep; 3(9):992-8. PubMed ID: 26048577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer.
    Karasaki T; Nagayama K; Kawashima M; Hiyama N; Murayama T; Kuwano H; Nitadori J; Anraku M; Sato M; Miyai M; Hosoi A; Matsushita H; Kikugawa S; Matoba R; Ohara O; Kakimi K; Nakajima J
    J Thorac Oncol; 2016 Mar; 11(3):324-33. PubMed ID: 26752676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade.
    Lotem M; Merims S; Frank S; Hamburger T; Nissan A; Kadouri L; Cohen J; Straussman R; Eisenberg G; Frankenburg S; Carmon E; Alaiyan B; Shneibaum S; Ozge Ayyildiz Z; Isbilen M; Mert Senses K; Ron I; Steinberg H; Smith Y; Shiloni E; Gure AO; Peretz T
    J Immunol Res; 2016; 2016():8121985. PubMed ID: 27294163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.